The serotonin hypothesis of schizophrenia: A historical case study on the heuristic value of theory in clinical neuroscience

Journal of the History of the Neurosciences

Volumn 13, Issue 3, 2004, Pages 277-291

  Baumeister, Alan A ^a   Hawkins, Mike F ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Depression; History of Medicine; Parkinson's Disease; Psychiatry; Reserpine; Schizophrenia; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN MONOAMINE; CATECHOLAMINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; IPRONIAZID; LYSERGIDE; MESCALINE; NEUROLEPTIC AGENT; PROMETHAZINE; RESERPINE; SEROTONIN; TRYPTOPHAN;

DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HISTORY OF MEDICINE; HUMAN; MEDICAL RESEARCH; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROSCIENCE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; RELIABILITY; REVIEW; SCHIZOPHRENIA; SEDATION; THEORY;

EUROPE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; NEUROSCIENCES; SCHIZOPHRENIA; SEROTONIN; UNITED STATES;

EID: 8144229605     PISSN: 0964704X     EISSN: None     Source Type: Journal    
DOI: 10.1080/09647040490510560     Document Type: Review

References (99)

1. Amin AH, Crawford TBB, Gaddum JH (1953): The distribution of 5-hydroxytryptamine and substance P in the central nervous system. Proceedings of 19th International Physiological Congress, Abstracts of Communications: 165-166.
2. Ashcroft GW, Sharman DF (1960): 5-hydroxyindoles in human cerebrospinal fluids. Nature 186: 1050-1051.
3. Barbeau A, Sourkes TL, Murphy GF (1962): Les catécholamines dans la maladie de parkinson. In: de Ajuriaguerra, ed., Monoamine et Systeme Nerveux Central. Geneva, Geoug and Paris, Masson, pp. 247-262.
4. Baumeister AA, Francis JL (2002): Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci 11: 265-277.
5. Baumeister AA, Hawkins MF (2001): Incoherence of neuroimaging studies of ADHD. Clin Neuropharmacol 24: 2-10.
6. Baumeister AA, Hawkins MF, Uzelac SM (2003): The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. J Hist Neurosci 12: 207-220.
7. Bertler Å, Carlsson A, Rosengren E (1956): Release by reserpine of catechol amines from rabbits' hearts. Naturwissenschaften 43: 521.
8. Bertler Å, Rosengren E (1959): Occurrence and distribution of dopamine in brain and other tissues. Experientia 15: 10-11.
9. Birkmayer W von, Hornykiewicz O (1961): Der L-3,4-Dioxyphenylalanin (=DOPA)-effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787-788.
10. Bleuler E (1911): Dementia Praecox or the Group of Schizophrenias, Leipzig. Translated by Zinkin J (1950), New York, International Universities Press.
11. Brodie BB, Bogdanski DF, Shore PA (1958): The action of psychotropic drugs (a biochemical and physiological interpretation). In: Rinkel M, Denber HCB, eds., Chemical Concepts of Psychosis. New York, Mcdowell/Obolensky, pp. 190-203.
12. Brodie BB, Pletscher A, Shore PA (1955): Evidence that serotonin has a role in brain function. Science 122: 968.
13. Brodie BB, Shore PA (1957): A concept for a role of serotonin and norepinephrine as chemical mediators in the brain. Ann NY Acad Sci USA 66: 631-642.
14. Brodie BB, Shore PA, Pletscher A (1956): Serotonin-releasing activity limited to rauwolfia alkaloids with tranquilizing action. Science 123: 992-993.
15. Brodie BB, Shore PA, Silver SL, Pulver R (1955): Potentiating action of chlorpromazine and reserpine. Nature 175: 1133-1134.
16. Brodie TG (1903): The perfusion of surviving organs. J Physiol 29: 266-275.
17. Carlsson A (1959): The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 2: 490-493.
18. Carlsson A, Corrodi H, Fuxe K, Hökfelt T (1969): Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-α-ethyl-meta-tyramine. Eur J Pharmacol 5: 357-366.
19. Carlsson A, Healy D (1996): The rise of neuropsychopharmacology: impact on basic and clinical neuroscience. In: The Psychopharmacologists. Interviews by David Healy. London, Chapman and Hall, pp. 51-80.
20. Carlsson A, Lindqvist M, Magnusson T (1957): 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180: 1200.
21. Cerletti A, Rothlin E (1955): Role of 5-hydroxytryptamine in mental diseases and its antagonism to lysergic acid derivatives. Nature 176: 785-786.
22. Coppen A (1967): The biochemistry of affective disorders. Brit J Psychiat 113: 1237-1264.
23. Coppen A, Healy D (1996): Biological psychiatry in Britain. In: The Psychopharmacologists. Interviews by David Healy. London, Chapman and Hall, pp. 265-286.
24. Coppen A, Shaw DM, Farrell JP (1963): Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1: 79-81.
25. Crane GE (1956a): The psychiatric side-effects of iproniazid. Am J Psychiat 112: 494-501.
26. Crane GE (1956b): Further studies on iproniazid phosphate. J Nerv Ment Dis 124: 322-331.
27. Dahlström A, Fuxe K (1964): A method for the demonstration of monoamine-containing nerve fibers in the central nervous system. Acta Physiol Scand 60: 293-295.
28. Deniker P (1983): Discovery of the clinical use of neuroleptics. In: Parnham MJ, Bruinvels J, eds., Discoveries in Pharmacology: Psycho- and Neuro-pharmacology. New York, Elsevier, Vol. 1, pp. 163-180.
29. Ehringer H, Hornykiewicz O (1960): Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkankungen des Extrapyramidalen Systems. Klin Wochenschr 38: 1236-1239.
30. Erspamer V, Asero B (1952): Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 169: 800-801.
31. Erspamer V, Ghiretti F (1951): The action of enteramine on the heart of molluscs. J Physiol 115: 470-481.
32. Everett GM, Toman JEP (1959): Mode of action of Rauwolfia alkaloids and motor activity. In: Masserman JH, ed., Biological Psychiatry. Proceedings of the Scientific Sessions of the Society of Biological Psychiatry San Francisco, May 1958. New York, Grune & Stratton, pp. 75-81.
33. Freud S (1939): Civilization and its Discontents. Translated From the German by Joan Riviere. London, Hogarth Press.
34. Gaddum JH (1953): Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. J Physiol 121: 15P.
35. Gaddum JH (1954): Drugs antagonistic to 5-hydroxytryptamine. In: Wolstenholme GEW, Cameron MP, eds., Ciba Foundation Symposium on Hypertension. Humoral and Neurogenic Factors. Boston, Little, Brown and Company, pp. 75-77.
36. Gaddum JH, Picarelli ZP (1957): Two kinds of tryptamine receptors. Br J Pharmacol 12: 323-328.
37. Gillin JC, Stoff DM, Wyatt RJ (1978): Transmethylation hypothesis: a review of progress. In: Lipton MA, DiMascio A, Killam KF, eds., Psychopharmacology: a generation of progress. New York, Raven Press, pp. 1097-1112.
38. Gouzoulis-Mayfrank E, Hermle L, Thelen B, Sass H (1998): History, rationale and potential of human experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry 31: 63-68.
39. Healy D (1987): The structure of psychopharmacological revolutions. Psychiat Dev 4: 349-376.
40. Healy D (1997): The Antidepressant Era. Cambridge, Harvard University Press.
41. Healy D (2002): The Creation of Psychopharmacology. Cambridge, Harvard University Press.
42. Hess WR (1954): Diencephalon. Autonomic and Extrapyramidal Functions. New York, Grune & Stratton.
43. Hoffer A, Osmond H, Smythies J (1954): Schizophrenia: a new approach. II. Result of a year's research. J Ment Sci 100: 29-45.
44. Hofmann A (1970): The discovery of LSD and subsequent investigations on naturally occurring hallucinogens. In: Ayd FJ, Blackwell B, eds., Discoveries in Biological Psychiatry. Philadelphia, J.B. Lippincott Company, pp. 91-106.
45. Holzbauer M, Vogt M (1956): Depression by reserpine of the noradrenaline concentration in the hypothalamus of the cat. J Neurochem 1: 8-11.
46. Janeway TC, Richardson HB, Park EA (1918): Experiments on the vasoconstrictor action of blood serum. Arch Int Med 21: 565-603.
47. Jung CG (1936): The Psychology of Dementia Praecox. Authorized Translation with an Introduction by A.A. Brill. Nervous and Mental Disease Monograph Series No. 3. Nervous and Mental Disease Publishing Company.
48. Kaplan A (1963): The Conduct of Inquiry. New York, Harper & Row.
49. Kety SS (1959): Biochemical theories of schizophrenia. Science 129: 1590-1596.
50. Kielholz P (1967): Die Wirkungsspektren der Antidepressiva. Med Welt 18: 537-538.
51. Kline NS (1954): Use of Rauwolfia serpentina Benth. in neuropsychiatric conditions. Ann NY Acad Sci 59: 107-132.
52. Kraepelin E (1919): Dementia Praecox and Paraphrenia. Edinburgh, E & S. Livingstone.
53. Kuhn TS (1962): The Structure of Scientific Revolutions. Chicago, University of Chicago Press.
54. Lauer JW, Inskip WM, Bernsohn J, Zeller EA (1958): Observations on schizophrenic patients after iproniazid and tryptophan. Arch Neurol Psychiat 80: 122-130.
55. Loomer HP, Saunders JC, Kline NS (1957): A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiat Res Rep 8: 129-141.
56. Marrazzi AS (1957): The effects of certain drugs on cerebral synapses. Ann NY Acad Sci 66: 496-507.
57. Moreau JJ (1845): Hashish and Mental Illness. Paris. Reprinted New York, Raven Press, 1973.
58. Müller JM, Schlittler E, Bein HJ (1952): Reserpin, der sedative Wirkstoff aus Rauwolfia serpentina Benth. Experientia 8: 338.
59. National Institute of Mental Health (1964): Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiat 10: 246-261.
60. Osmond H (1958): Chemical concepts of psychosis. Historical contributions. In: Rinkel M, Denber HCB, eds., Chemical Concepts of Psychosis. Proceedings of the Symposium on Chemical Concepts of Psychosis Held at the Second International Congress of Psychiatry in Zurich, Switzerland, September 1-7, 1957. New York, Mc Dowell/Obolensky, pp. 3-26.
61. Osmond H, Smythies J (1952): Schizophrenia: a new approach. J Ment Sci 98: 309-315.
62. Owens MJ, Risch SC (2001): Atypical antipsychotics. In: Schatzberg AF, Nemeroff CB, eds., Essentials of Clinical Psychopharmacology. Washington DC, American Psychiatric Publishing, Inc., pp. 125-154.
63. Peroutka SJ, Howell TA (1994): The molecular evolution of G protein-coupled receptors: focus on 5-hydroxytryptamine receptors. Neuropharmacol 33: 319-324.
64. 3H]-spiroperidol. Mol Pharmacol 16: 687-699.
65. Pollin W, Cardon PV, Kety SS (1961): Effects of amino acid feedings in schizophrenic patients treated with iproniazid. Science 133: 104-105.
66. Rapport MM (1949): Serum vasoconstrictor (serotonin) V. the presence of creatinine in the complex. A proposed structure of the vasoconstrictor principle. J Biol Chem 180: 961-969.
67. Rapport MM, Green AA, Page IH (1948): Partial purification of the vasoconstrictor in beef serum. J Biol Chem 174: 735-741.
68. Robitzek EH, Selikoff IJ (1952): Hydrazine derivatives of isonicotinic acid (Rimifon, Marsilid) in the treatment of active progressive caseouspneumonic tuberculosis. Am Rev Tuber 65: 402-428.
69. Robitzek EH, Selikoff IJ, Ornstein GG (1952): Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid. Quart Bull Sea View Hosp 13: 27-51.
70. Rodnight R (1961): Body fluid indoles in mental illness. Int Rev Neurobiol 3: 251-292.
71. Sanders-Bush E, Mayer SE (2001): 5-hydroxytryptamine (serotonin): receptor agonists and antagonists. In: Hardman JG, Limbird LE, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, McGraw Hill, 10th edition, pp. 269-290.
72. Selikoff IJ, Robitzek EH, Ornstein GG (1952): Toxicity of hydrazine derivatives of isonicotinic acid in the chemotherapy of human tuberculosis. Quart Bull Sea View Hosp 13: 17-26.
73. Shaw E, Woolley DW (1953): Yohimbine and ergot alkaloids as naturally occurring antimetabolites of serotonin. J Biol Chem 203: 979-989.
74. Shaw E, Woolley DW (1956): Some serotoninlike activities of lysergic acid diethylamide. Science 124: 121-122.
75. Shore PA, Mead JAR, Kuntzman RG, Spector S, Brodie BB (1957): On the physiologic significance of monoamine oxidase in brain. Science 126: 1063-1064.
76. Shore PA, Silver SL, Brodie BB (1955a): Interaction of serotonin and lysergic acid diethylamide (LSD) in the central nervous system. Experientia 11: 272-273.
77. Shore PA, Silver SL, Brodie BB (1955b): Interaction of reserpine, serotonin, and lysergic acid diethylamide in brain. Science 122: 284-285.
78. Shorter E (1997): A History of Psychiatry. New York, John Wiley & Sons.
79. Smith B, Prockop DJ (1962): Central-nervous-system effects of ingestion of L-tryptophan by normal subjects. New Eng J Med 267: 1338-1341.
80. Smith JA (1953): The use of the isopropyl derivative of isonicotinylhydrazine (Marsilid) in the treatment of mental disease. Am Practitioner 4: 519-520.
81. Stevens LT (1884): The action of intermittent pressure and of defibrinated blood upon the bloodvessels of the frog and the terrapin. Studies from the Biological Laboratory, Johns Hopkins University 3: 99-119.
82. Stewart GN, Zucker TF (1913): A comparison of the action of plasma and serum on certain objects used in biological tests for epinephrin. J Exp Med 17: 152-173.
83. Swazey JP (1974): Chlorpromazine in Psychiatry. A Study of Therapeutic Innovation. Cambridge, The MIT Press.
84. Thudichum JLW (1884): A Treatise on the Chemical Constitution of the Brain. London, Bailliere, Tindall, and Cox. Reprinted Hamden, Connecticut, Archon Books, 1962.
85. Twarog BM (1954): Responses of a molluscan smooth muscle to acetylcholine and 5-hydroxytryptamine. J Cell Comp Physiol 44: 141-163.
86. Twarog BM (1988): Serotonin: history of a discovery. Comp Biochem Physiol 91C: 21-24.
87. Twarog BM, Page IH (1953): Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol 175: 157-161.
88. Udenfriend S (1959): Biochemistry of serotonin and other indolamines. Vitamins Hormones 17: 133-151.
89. Udenfriend S, Weissbach H, Bogdanski DF (1957): Increase in tissue serotonin following administration of precusor 5-hydroxytryptophan. J Biol Chem 224: 803-810.
90. Valenstein ES (1998): Blaming the Brain. New York, Free Press.
91. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D (1998): Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897-3902.
92. Welsh JH (1953): Excitation of the heart of venus mercenaria. Arch exper Path u Pharmakol 219: S23-S29.
93. Whitaker R (2002): Mad in America. Bad Science, Bad Medicine, and the Enduring Mistreatment of the Mentally Ill. Cambridge, Perseus Publishing.
94. Wilkins RW, Judson WE (1953): Problems arising from the use of hypotensive drugs in hypertensive patients. Trans Ass Am Physicians 66: 175-189.
95. Woolley DW (1962): The Biochemical Bases of Psychosis or the Serotonin Hypothesis about Mental Disease. New York, John Wiley and Sons.
96. Woolley DW, Shaw E (1953): Yohimbine and ergotoxin as naturally-occurring antimetabolites of serotonin. Fed Proc 12: 293.
97. Woolley DW, Shaw E (1954): A biochemical and pharmacological suggestion about certain mental disorders. Science 119: 587-588.
98. Woolley DW, Shaw EN (1957): Evidence for the participation of serotonin in mental processes. Ann NY Acad Sci USA 66: 649-665.
99. Zeller EA, Barsky J, Fouts JR, Kirch-Heimer WF, Van Orden LS (1952): Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia 8: 349-350.